Roche's implant for chronic eye disorder wins U.S. approval [Financial Post (Toronto, Ontario, Canada)]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Financial Post
causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. Elon Musk is on track to become the world's first trillionaire Advertisement The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy. Advertisement Article content Anti-VEGF therapies, the current standard of care for wet AMD, work against a protein said to play a key role in the disease. They require patients to receive eye injections as often as monthly to preserve vision. Susvimo is intended for those who have previously responded to at least two anti-VEGF injections and needs
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ‘ready' to start developing drugs [TechCrunch]TechCrunch
- Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Swiss pharmaceutical maker Roche says group sales dropped 6% [Yahoo! Finance]Yahoo! Finance
- Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology [Yahoo! Finance]Yahoo! Finance